CLINICAL EVALUATION OF IFN BETA1B IN COVID-19 PNEUMONIA: A RETROSPECTIVE STUDY https://doi.org/10.1101/2020.05.15.20084293 In this retrospective cohort study, 256 patients (106 patients in interferon group and 150 patients in control group) were analyzed. In the interferon group, more patients received hydroxychloroquine… Continue reading "(19 May 2020) Interferon beta- no significant impact on in-hospital survival"
Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1101/2020.05.14.20094144 In an observational clinical cohort study, of the 53 SARS-CoV-2 patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a… Continue reading "(18 May 2020) Sarilumab- promising clinical benefit and good safety"
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 https://link.springer.com/article/10.1007%2Fs11427-020-1732-2 In this retrospective study, 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan were included. All 550 patients received comparable basic treatments including… Continue reading "(18 May 2020) Hydroxychloroquine- effective in reducing the fatality of critically ill patients"
Early experience with remdesivir in SARS-CoV-2 pneumonia https://link.springer.com/article/10.1007/s15010-020-01448-x This case report describes an early experience with remdesivir in four critically ill COVID-19 patients admitted to the Monaldi Hospital, Naples, Italy. Patients received a 200 mg loading dose, followed by 100… Continue reading "(18 May 2020) Remdesivir- preliminary evidence of in-vivo virological effect"
Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration https://doi.org/10.1101/2020.05.13.20100081 A total of 94 patients with COVID-19 ARDS were analyzed. 44 were in the study group and 50 in the control group. Average HS score… Continue reading "(16 May 2020) Tocilizumab- Higher survival rate and outcome"
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial https://www.bmj.com/content/369/bmj.m1849 This study (conducted during the outbreak of covid-19 in China -ChiCTR2000029868) is the first randomised controlled trial evaluating administration of hydroxychloroquine in patients… Continue reading "(16 May 2020) Hydroxychloroquine- no evidence for negative conversion of SARS-CoV-2"
FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS https://doi.org/10.1016/j.chom.2020.05.007 This report comprises of data from the treatment of eight severe COVID-19 pneumonia patients– seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in… Continue reading "(16 May 2020) Anakinra- beneficial for treating severe COVID-19 patients with sHLH"
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. https://doi.org/10.1016/j.jinf.2020.03.002 In this retrospective cohort study, 16 patients received oral arbidol and LPV/r in the combination group and 17 received oral LPV/r only in… Continue reading "(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r"
Systemic corticosteroids show no benefit in severe and critical COVID-19 patients in Wuhan, China: A retrospective cohort study https://doi.org/10.1101/2020.05.11.20097709 In a retrospective cohort study in Wuhan, corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to… Continue reading "(14 May 2020) Corticosteroids- show no good in COVID-19"
In Vitro Inhibition of SARS-CoV-2 Infection by Bovine Lactoferrin https://doi.org/10.1101/2020.05.13.093781 Using an antiviral assay based on quantitative reverse transcription-polymerase chain reaction (qRT-PCR), it was found that Bovine lactoferrin (bLf) reduced progeny virus yield by up to ~84,6% in African green… Continue reading "(13 May 2020) Lactoferrin-significantly interfere with SARSCoV-2 replication in vitro at 1 mg/mL"
